BUSINESSSTAT NEWS
Gilead and Merck’s latest trial success and flop
GSK acquired Nuvalent, a biotech company with two drugs under FDA review for targeting genetic mutations in lung cancer, for $10.6 billion. Approval decisions for the drugs are expected later this year.
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
- GSK is acquiring lung cancer biotech Nuvalent in its biggest deal in over a decade
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
- Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion